Koch, ACox, HMizrahi, V2024-09-262024-09-262018-06-06Koch A, Cox H, Mizrahi V. Drug-resistant tuberculosis: challenges and opportunities for diagnosis and treatment. Curr Opin Pharmacol. 2018 Oct;42:7-15. doi: 10.1016/j.coph.2018.05.013https://doi.org/10.1016/j.coph.2018.05.013https://pubmed.ncbi.nlm.nih.gov/29885623/https://doi.org/10.1016/j.coph.2018.05.013https://hdl.handle.net/11288/597543With an estimated incidence of 490000 cases in 2016, multidrug resistant tuberculosis (TB), against which key first-line anti-tuberculars are less efficacious, presents major challenges for global health. Poor treatment outcomes coupled with a yawning treatment gap between those in need of second-line therapy and those who receive it, underscore the urgent need for new approaches to tackle the scourge of drug-resistant TB. Against this background, significant progress has been made in understanding the complex biology of TB drug resistance and disease pathogenesis, and in establishing a pipeline for delivering new drugs and drug combinations. In this review, we highlight the challenges of drug-resistant TB and the ways in which new advances could be harnessed to improve treatment outcomes.enAttribution 3.0 United Stateshttp://creativecommons.org/licenses/by/3.0/us/Drug-resistant tuberculosisGlobal healthTreatmentTBSDG-03 Good health and well-beingArticleCurrent Opinion in Pharmacology